SIC
HZNP

SJS Investment Consulting’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

SJS Investment Consulting’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6
Closed -$695 – 1676
2023
Q3 		$695 Sell
6
-3
-33% -$322 ﹤0.01% 1090
2023
Q2 		$926 Hold
9
– – ﹤0.01% 931
2023
Q1 		$983 Sell
9
-1
-10% -$111 ﹤0.01% 901
2022
Q4 		$1.14K Sell
10
-3
-23% -$249 ﹤0.01% 882
2022
Q3 		$0 Buy
+13
New +$908 ﹤0.01% 1699
2022
Q1 		$0 Buy
+3
New +$292 ﹤0.01% 1492

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SJS Investment Consulting's HZNP Position: Q4 2023 in Review

SJS Investment Consulting sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 6 shares — an estimated $695 sold.

SJS Investment Consulting first reported a position in HZNP in Q1 2022 and held it in 6 quarters. The position peaked at $1.14K in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • SJS Investment Consulting reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • SJS Investment Consulting sold 6 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $695.
  • SJS Investment Consulting first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 6 quarters.
  • SJS Investment Consulting's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.14K in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on SJS Investment Consulting's 13F filing for Q4 2023, filed 16 Jan 2024.